<DOC>
	<DOCNO>NCT02222974</DOCNO>
	<brief_summary>The objective study obtain information safety , tolerability pharmacokinetics BIIR 561 CL single intravenous administration increase dos healthy male volunteer</brief_summary>
	<brief_title>Single Increasing Dose Tolerance Study Healthy Male Volunteers BIIR 561 CL</brief_title>
	<detailed_description />
	<criteria>Healthy male volunteer Age 21 50 year Broca index 20 % +20 % Written inform consent prior admission study Medical examination , laboratory test ECG judge investigator differ significantly normal clinical value Known gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Known disease central nervous system ( CNS ) ( epilepsy ) , CNS trauma medical history psychiatric neurological disorder Known history orthostatic hypotension , faint spell blackouts Chronic relevant acute infection Allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24 hour ) within least one month less ten halflives respective drug enrolment study Intake drug might influence result trial week previous start study Participation another study investigational drug within last two month precede study Smoker ( &gt; 10 cigarette 3 cigar 3 pipes/day ) Alcohol use 60 g per day Drug dependency Excessive physical activity ( e.g . competitive sport ) within last week study Blood donation within last 4 week ( &gt; = 100 ml )</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>